Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2016-02-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 24 pages 719.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D For the Half Year Ended 31 December 2015' and contains detailed financial statements including Consolidated Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, and Statement of Cash Flows for the half year ended 31 December 2015. It includes Directors' Report, Auditor's Independence Declaration, and notes to the financial statements. The presence of comprehensive financial data and analysis for a half-year period indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2016
2016-02-28 English
Imugene Results for December Half Year 3 pages 140.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Imugene announces half-year results for period ended 31 December 2015' and contains detailed financial and operational information for the half-year period, including loss figures, cash position, R&D expenses, and clinical trial updates. It covers a six-month period and provides substantive financial data and business highlights, which is characteristic of an Interim / Quarterly Report. The document length is over 6000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is a full Annual Report (10-K) or just an earnings release (ER) with key highlights only. Therefore, the document fits best as an Interim / Quarterly Report (IR). H1 2016
2016-02-28 English
Imugene to present at the RedChip Global Online Conference 2 pages 126.2KB
Investor Presentation Classification · 90% confidence The document is an announcement about Imugene Limited presenting at the RedChip Global Online Microcap Conference. It provides details about the event, the company's business, and contact information. There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification. The content is primarily an investor presentation announcement, describing the upcoming presentation and webcast. Given the nature of the document as an announcement of a presentation event rather than the presentation itself or a financial report, the most appropriate classification is Investor Presentation (IP). The document length is under 5,000 characters, but it is not merely announcing a report publication; it is announcing a presentation event. Therefore, the classification is IP with high confidence.
2016-02-09 English
Appendix 4C - quarterly 5 pages 152.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarter ended 31st December 2015 and includes substantive financial data and analysis for that quarter. The length of the document (7131 characters) and the detailed financial content indicate it is a financial report rather than a brief announcement or certification. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). Q2 2015
2016-01-26 English
Partnership to Develop Mimotope Immuno-Oncology Platform 3 pages 57.3KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a partnership between Imugene Limited and the Medical University of Vienna to develop a new immuno-oncology platform. It discusses the collaboration, intellectual property rights, and the scientific background of the mimotope vaccines. There is no financial data, regulatory filing references, or detailed report content. The document is a corporate announcement about a partnership and research collaboration, not a financial report, regulatory filing, or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or corporate news update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2016-01-19 English
Final Director's Interest Notice (OB) 2 pages 33.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's relevant interests in securities, including holdings and contracts. This type of document is a report of personal share transactions or holdings by company directors, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not financial results or other report types.
2016-01-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.